SCHEMBL7207698

SCHEMBL7207698

CCc1csc(-c2ccc(-c3csc([C@H](C)[C@](O)(Cn4cncn4)c4ccc(F)cc4F)n3)cc2)n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 17/20 0.74
KCNH2 Q12809 3/20 0.74
ABCG2 Q9UNQ0 1/20 0.65
CYP2C9 P11712 11/20 0.52
CYP2C19 P33261 11/20 0.52
LMNA P02545 2/20 0.52
CYP2B6 P20813 1/20 0.52
CYP3A5 P20815 1/20 0.52
CYP3A7 P24462 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP3A43 Q9HB55 1/20 0.52
CYP46A1 Q9Y6A2 1/20 0.52
CYP1A2 P05177 6/20 0.45
CYP2D6 P10635 6/20 0.45
HSP90AA1 P07900 1/20 0.45
CYP19A1 P11511 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
ADRA1A P35348 1/20 0.45
CYP51A1 Q16850 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7209047 0.91 CYP3A4 (0.76) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7208403 0.91 CYP3A4 (0.76) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7208406 0.89 CYP3A4 (0.74) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7212702 0.88 CYP3A4 (0.57) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7207761 0.88 CYP3A4 (0.72) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7207669 0.87 CYP3A4 (0.75) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL7801613 0.86 CYP3A4 (0.68) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
Ravuconazole SCHEMBL939025 0.85 CYP3A4 (1.00) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
Ravuconazole SCHEMBL13169577 0.85 CYP3A4 (1.00) CYP3A4KCNH2ABCG2CYP2C9CYP2C19
SCHEMBL14012888 0.85 CYP3A4 (0.85) CYP3A4KCNH2ABCG2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1286988-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES Basilea Pharmaceutica AG (CH) 2003-03-05 EP claimed
US-20010047017-A1 Azole derivatives HOFFMANN-LA ROCHE, INC. 2001-11-29 US claimed
US-6319933-B1 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides BASILEA PHARMACEUTICA AG (CH) 2001-11-20 US claimed
WO-2001079196-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES BASILEA PHARMACEUTICA AG (CH) 2001-10-25 WO claimed
EP-1286988-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES Basilea Pharmaceutica AG (CH) 2003-03-05 EP disclosed
US-20010047017-A1 Azole derivatives HOFFMANN-LA ROCHE, INC. 2001-11-29 US disclosed
US-6319933-B1 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides BASILEA PHARMACEUTICA AG (CH) 2001-11-20 US disclosed
WO-2001079196-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES BASILEA PHARMACEUTICA AG (CH) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047017-A1 Azole derivatives ERG28, CYP51A1, CYP3A5 CYP3A4 17/4885KCNH2 1173/4885ABCG2 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.